NEW YORK – Caris Life Sciences has detailed the development and validation of its AI-driven tumor origin predictor, MI GPSai, which the firm has been offering clinically since December 2019 to help direct treatment for patients with carcinoma of unknown primary (metastatic cancer that has no clear origin) and, in certain cases, to inform physicians of possible cases of non-CUP misdiagnosis.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try GenomeWeb Premium now.
You may already have institutional access!
Check if I qualify.
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.